Benefits
Hypertriglyceridemia Reduction
Strongest evidence — 2-4 g/day EPA+DHA reduces triglycerides 20-50%. Pharmaceutical fish oils (Vascepa®, Lovaza®) FDA-approved for severe hypertriglyceridemia (>500 mg/dL). Mechanism: reduced hepatic VLDL production.
Cardiovascular Risk Reduction (Disputed)
REDUCE-IT trial (Bhatt 2019) showed icosapent ethyl (4 g/day pure EPA) reduced cardiovascular events 25% in high-risk patients on statins. STRENGTH trial (Nicholls 2020) of EPA+DHA combination did NOT show benefit. Disputed whether benefit is specific to EPA, dose-dependent, or related to mineral oil placebo effects in REDUCE-IT. FDA approved Vascepa for CV risk reduction 2019.
Anti-Inflammatory Effects
EPA-derived eicosanoids (resolvins, protectins) have anti-inflammatory and pro-resolving effects. Multiple trials show fish oil reduces inflammatory markers (CRP, IL-6, TNF-α) modestly. Mechanism for various applications (joint pain, autoimmune support).
Pregnancy / Fetal Brain Development
DHA crucial for fetal brain and retinal development. RCTs (Carlson 2013, others) show maternal DHA supplementation improves infant visual and cognitive development. Major obstetric organizations recommend 200-300 mg DHA daily during pregnancy and lactation.
Rheumatoid Arthritis / Autoimmune Adjunct
Multiple RCTs show fish oil reduces joint pain, morning stiffness, and NSAID requirements in RA. Adjunct to standard treatment, not replacement. 2.7-3.6 g/day EPA+DHA.
Major Depressive Disorder Adjunct
Multiple meta-analyses (Mocking 2016, others) show EPA-predominant fish oil reduces depression scores in major depressive disorder. EPA-rich preparations more effective than DHA-rich; doses ~1-2 g/day EPA.
Mechanism of action
Eicosanoid Pathway Modulation
EPA competes with arachidonic acid (AA, omega-6) in phospholipase A2 release and cyclooxygenase/lipoxygenase pathways. EPA-derived eicosanoids (PGE3, LTB5, resolvins, protectins) have less inflammatory and more pro-resolving activity than AA-derived eicosanoids (PGE2, LTB4). Foundational anti-inflammatory mechanism.
Cell Membrane Composition
EPA and DHA incorporate into cell membrane phospholipids — affecting membrane fluidity, receptor function, and signaling. Particularly important in: cardiac muscle, retina, brain (DHA is ~25% of brain phospholipids).
Hepatic VLDL Reduction
Fish oil reduces hepatic VLDL synthesis and increases beta-oxidation of fatty acids — basis for triglyceride-lowering effect.
Antiarrhythmic Properties
Fish oil EPA modulates cardiac sodium and calcium channels — antiarrhythmic effects (relevant for sudden cardiac death prevention; mechanistically interesting; clinical evidence mixed).
Clinical trials
RCT of icosapent ethyl (Vascepa®, 4 g/day pure EPA) vs mineral oil placebo in 8,179 statin-treated CV-risk patients for ~5 years.
8,179 statin-treated patients with elevated triglycerides and high CV risk.
25% reduction in major adverse cardiovascular events. FDA approved Vascepa for CV risk reduction in 2019. Subsequently disputed: STRENGTH trial of EPA+DHA failed; some attribute REDUCE-IT effect to mineral oil placebo causing harm to control group.
RCT of carboxylic acid formulation of EPA+DHA (4 g/day) vs corn oil placebo in 13,078 high-CV-risk patients on statins for ~3.5 years.
13,078 statin-treated CV-risk patients.
FAILED to show CV event reduction; trial stopped for futility. Contributed to controversy about whether REDUCE-IT result reflects EPA-specific benefit, dose, or placebo issues. Limited enthusiasm for EPA+DHA combination CV trials.
About this ingredient
FISH OIL is OIL EXTRACTED from oily fish — primarily ANCHOVIES, SARDINES, MACKEREL, HERRING, MENHADEN, SALMON.
KEY ACTIVES: EPA (eicosapentaenoic acid, 20-carbon omega-3) and DHA (docosahexaenoic acid, 22-carbon omega-3). Different fish provide different EPA:DHA ratios. FISH OIL FORMS: (1) NATURAL TRIGLYCERIDE — the form found in fish; (2) ETHYL ESTER — semi-synthetic form created by transesterification; higher EPA/DHA concentration possible but somewhat reduced absorption; (3) RE-ESTERIFIED TRIGLYCERIDE — ethyl ester converted back to triglyceride form; better absorption than ethyl ester; more processing; (4) PHOSPHOLIPID — found in krill oil (separate entry); (5) FREE FATTY ACID — used in some pharmaceutical preparations. PHARMACEUTICAL FISH OILS: (1) LOVAZA® / OMACOR® — combination EPA+DHA ethyl esters; FDA-approved for hypertriglyceridemia; (2) VASCEPA® / EPADEL® — pure EPA (icosapent ethyl); FDA-approved for hypertriglyceridemia AND CV risk reduction (2019); (3) EPANOVA® — EPA+DHA free fatty acid form; approved but no longer marketed.
EVIDENCE-BASED USES: (1) HYPERTRIGLYCERIDEMIA — strongest evidence; (2) Cardiovascular risk reduction (disputed; pure EPA may be effective; combination data mixed); (3) Anti-inflammatory effects; (4) PREGNANCY/FETAL DEVELOPMENT — DHA crucial; (5) Rheumatoid arthritis adjunct; (6) Major depressive disorder adjunct (EPA-predominant); (7) Age-related macular degeneration adjunct (AREDS2 — modest); (8) ADHD adjunct (modest).
CRITICAL CAUTIONS: (1) ATRIAL FIBRILLATION — REDUCE-IT and other high-dose EPA trials showed INCREASED AFib incidence; relevant for those with arrhythmia history; consult cardiologist; (2) BLEEDING RISK at high doses (>3 g/day); pre-surgery discontinuation 1-2 weeks for high-dose use; (3) MERCURY/HEAVY METAL CONTAMINATION — concern with low-quality products; reputable brands provide IFOS (International Fish Oil Standards) or USP certification, third-party testing; small fish (sardines, anchovies) accumulate less mercury than large predatory fish (tuna, swordfish); (4) OXIDATION / RANCIDITY — fish oil oxidizes easily; rancid oil may be PRO-INFLAMMATORY rather than anti-inflammatory; reputable brands include antioxidants (vitamin E, rosemary extract) and use opaque packaging; refrigerate after opening; if smells/tastes rancid (intensely fishy/foul), discard; (5) DOSE — general health: 1-2 g/day combined EPA+DHA; cardiovascular: pharmaceutical 4 g/day; hypertriglyceridemia: 2-4 g/day; pregnancy: 200-1,000 mg DHA/day; depression: 1-2 g/day EPA-predominant; (6) RATIO — for inflammation/depression: EPA-predominant preferred (>2:1 EPA:DHA); for pregnancy/cognition: DHA-predominant or balanced; (7) PRESCRIPTION VS SUPPLEMENT — for severe hypertriglyceridemia or post-MI CV risk, prescription versions provide standardized doses, FDA quality oversight, insurance coverage; supplement quality variable; (8) VEGAN/VEGETARIAN — algal oil DHA is vegan EPA/DHA source; ALA from flax/chia converts poorly to EPA/DHA in humans; (9) PREGNANCY — DHA recommendation universal; mercury concern relevant — choose tested low-mercury sources; (10) COD LIVER OIL DIFFERENCE — cod liver oil contains EPA+DHA PLUS vitamins A and D (significant amounts); separate entry; risk of vitamin A toxicity at high doses; (11) STORAGE — refrigerate after opening; protect from light/heat; consume within 2-3 months of opening; (12) TIMING — with meals (especially fat-containing meals) for absorption; (13) SOURCING — sustainable fishing concerns; choose brands with sustainable sourcing certifications (MSC, Friend of the Sea); (14) The fish oil evidence base is genuinely strong for several indications — among the most evidence-based supplements; quality, dose, and form matter substantially.